Press Releases

07.19.2021

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

07.19.2021

Pfizer Announces New Investor Relations Leader

07.08.2021

Collaboration Between Abbvie, Biogen And Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants To Human Health And Disease.

07.08.2021

Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

06.30.2021

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

06.24.2021

Pfizer Declares Third-Quarter 2021 Dividend

06.23.2021

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

06.16.2021

Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

06.16.2021

Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts

06.10.2021

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

06.08.2021

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

05.28.2021

Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents